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METHODS: A decision-tree model was constructed to
determine the total expected cost per patient for a four-
month time period following an initial angioplasty. The
model used clinical data from the Coronary Angioplasty
Amlodipine Restenosis Study (CAPARES), a four-month,
multicenter, double-blind, placebo-controlled trial con-
ducted to investigate the effect of amlodipine on resteno-
sis and clinical events in patients undergoing PTCA. Clin-
ical endpoints of interest included MI, repeat PTCA,
CABG, and all-cause mortality. Clinical experts from
Canada and Norway were enlisted and a modified Delphi
study approach was used to estimate the amount of
health-care resources consumed for each clinical out-
come.
RESULTS: The adjunctive use of amlodipine improved
the four-month success rate of angioplasties by 9.4%
(83.7% vs 93.1%). In other words, there was a decrease
in the number of adverse clinical endpoints after an an-
gioplasty. There was an absolute reduction of 2.0%,
4.7%, and 2.7% in the rate of MI, PTCA, and CABG, re-
spectively. The total expected cost per patient using am-
lodipine was $6,398 (US$4,328) in Canada and kr35,652
(US$4,004) in Norway. The total expected cost per pa-
tient not using amlodipine was $6,519 (US$4,410) in
Canada and kr37,150 (US$4,172) in Norway. The model
demonstrated the magnitude of the potential savings re-
sulting from the improved clinical outcomes for patients
using amlodipine with PTCA. Overall, fewer health re-
sources were utilized by amlodipine patients, resulting in
savings in total expected cost of treatment of $121
(US$82) in Canada and kr1, 498(US$168) in Norway.
CONCLUSIONS: The adjunctive use of amlodipine is a
cost-effective therapeutic strategy to achieve more favor-
able clinical outcomes in patients undergoing PTCAs in
Canada and Norway.
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Levosimendan is a novel intravenous drug that increases
the calcium sensitivity of cardiac myofilaments, improves
haemodynamic function and symptoms, and decreases rel-
ative mortality of patients with low-output heart failure.
OBJECTIVE: To estimate the cost-effectiveness of treat-
ment with levosimendan compared to dobutamine in pa-
tients with severe low-output heart failure.
METHODS: The economic evaluation was based on a
European cinical trial (LIDO), in which 203 patients with
severe heart failure were randomised to 24h infusion
with either levosimendan or dobutamine. Survival and re-
source utilisation data were collected for six months, and
survival was extrapolated up to three years based on data
from the CONSENSUS trial. Costs were based on drug
usage and hospitalisation in the LIDO trial and the six-
month follow-up. The price of levosimendan was arbi-
trarily set at €668 (USD 600) per 5 ml vial, whereas the
mean actual cost of dobutamine in the eight countries
participating in the study was calculated (€13.70 per
vial). The mean cost of a hospital day in the eight coun-
tries was used (basis 1998).
RESULTS: The mean survival over six months was 157
(SD 51.5) days in the levosimendan group and 139 (SD
64.0) days in the dobutamine group (p  .01). When ex-
trapolated up to three years, the gain in life expectancy
was estimated at 0.35 years (discounted by 3%). Levosi-
mendan increased the average cost per patient by
€1,154. The incremental cost per life year saved (LYS)
was €3,340. When accounting for a cost in added years
of life, the incremental cost per LYS was higher, as ex-
pected. For example in Sweden, the cost per LYS in-
creased from €3,000 to €20,800.
CONCLUSIONS: The cost per LYS using levosimendan,
both with and without accounting for costs in added
years of life, compares favourably with other cost-effec-
tiveness analyses in cardiology, e.g. USD 33,000/LYS for
TPA treatment in the GUSTO trial.
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OBJECTIVE: Bradycardia is a common condition char-
acterized by a heart rate of less than 60 beats per minute.
Among patients with bradycardia, atrial tachyarrhyth-
mias may also be present at the time of pacemaker im-
plant, or may subsequently develop during the lifetime of
the device. We conducted a study in the US, Germany
and the UK to assess the additional burden of health-care
utilization and associated costs imposed by atrial tachy-
arrhythmia among bradycardia patients.
METHODS: In the US, electronic claims including hospi-
tal inpatient admissions, emergency room admissions,
outpatient physician visits, outpatient tests and proce-
dures, and pharmacy claims data were obtained from a
large-group model managed-care organization with broad
geographic representation. In Europe, resource utilization
data were collected via a survey of cardiologists (n  5 in
Germany, n  4 in UK). For the survey, two patient
groups were defined: patients with bradycardia and no
coexisting atrial tachyarrhythmias, and those with co-ex-
isting diagnoses of bradycardia and atrial tachyarrhyth-
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mias. Health-care utilization and cost data for each of the
two patient categories were averaged and annualized.
Costs were converted from local currencies to Euros.
RESULTS: The mean annual health-care costs in patients
with bradycardia alone was 7,787 EUR (95%CI 6,176 to
10,040 EUR) in the US, 3,860 EUR in Germany, and
3,765 EUR in the UK compared to 22,043 EUR (95%CI:
15,060 to 30,759 EUR) in the US, 14,720 EUR in Ger-
many, and 10,407 EUR in the UK for patients with
bradycardia and atrial tachycardias. Atrial tachycardia
results in an additional two- to three-fold increase in
costs per year. The main cost driver in the US and Ger-
many was hospitalizations whereas the main cost driver
in the UK was the cost of procedures.
CONCLUSION: Atrial tachyarrhythmias impose a large
incremental burden on health-care utilization and costs in
bradycardia patients.
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OBJECTIVE: The purpose of this study was to examine
the effect of amlodipine treatment on cardiovascular dis-
ease (CVD) related hospital admissions and the corre-
sponding costs in patients with coronary artery disease
(CAD) in Spain.
METHODS: This analysis used data from Prospective
Randomized Evaluation of the Vascular Effects of Nor-
vasc Trial (PREVENT), a double-blind, randomized, pla-
cebo-controlled, multi-center clinical trial. A decision-
tree model was used to analyze the expected incremental
cost of amlodipine treatment relative to placebo. A sensi-
tivity analysis was conducted to examine the robustness
of the study outcome. The hospital costs were estimated
using the DRG’s from the Medicare adjusted to the me-
dian of a local hospital stay cost (Catalonian area).
RESULTS: Amlodipine significantly reduced the number
of CVD-related hospital admissions and procedures in pa-
tients with CAD relative to placebo. The expected CVD-
related hospital cost per patient in the placebo group ex-
ceeded costs for patients in the amlodipine group. The ex-
pected savings of CVD-related hospitalizations ranged
from 0 to 331 Euros per patient over the trial period in
1997 Spanish pesetas when the cost to charge ratio was
changed from 0.66 to 1.2. The total expected costs for the
amlodipine group were 1,723.5 Euros (533 for no CVD
hospitalization and 1190 for CVD hospitalization) while
the total expected costs for the placebo group were 1929
Euros (119 for No CVD hospitalization and 1810 for
CVD hospitalization). At the breakeven point (the cost to
charge ratio  0.66), the amlodipine treatment still offset
the drug cost of amlodipine.
CONCLUSIONS: Use of amlodipine can reduce CVD-
related hospital admissions and associated costs in pa-
tients with coronary artery disease. Amlodipine is a cost-
saving agent in the treatment of patients with coronary
artery disease.
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OBJECTIVES: To install a world-wide-web (WWW, inter-
net) -based registry for the observation of treatment patterns
for unstable Angina Pectoris (uAP) and to estimate the eco-
nomic burden of uAP in Germany from the perspective of
the statutory health insurance (Gesetzliche Krankenver-
sicherung) and of hospitals as service providers.
METHODS: Prospective, bottom-up, cross-sectional cost-
of-illness (COI) study. Three hundred sixteen patients con-
secutively included between November 2000 and May
2001 were documented via an Internet-based registry us-
ing standardized documentation forms. Inclusion and ex-
clusion criteria were pre-defined. Fifteen centers of differ-
ent healthcare levels (10 university hospitals, 1 specialized
hospital, 4 general hospitals) participated. Direct costs (for
diagnostic, medical treatment, surgery, drug therapy) and
indirect costs (due to lost productivity) associated with in-
patient treatment due to uAP were considered.
RESULTS: Mean age of patients was around 65 years for
females (34%) and 69 years for males (66%). In about
99% of cases, uAP was diagnosed at hospital admission:
47% were hospitalized as emergency cases; 26% were re-
ferred from other hospitals; 26% from office-based phy-
sicians. Mean hospital stay lasts 8.3 days per patient, 6.8
days of them spent in intensive care. Angiography or an-
gioplasty were performed on 78% of patients. About 4%
of patients underwent heart surgery, most of them for tri-
ple coronary bypass. 30% of patients received one of the
new platelet aggregation inhibitors (Abciximab, Eptifi-
batide, Tirofiban) during hospitalization.
CONCLUSIONS: Because the registry is still ongoing, cost
data are under evaluation, but will be finalized for poster
presentation. Treatment with platelet aggregation inhibi-
tors is still not very common, despite being recommended
by German therapy guidelines for uAP treatment.
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OBJECTIVE: With a prevalence up to 40% in the adult
population, chronic venous insufficiency (CVI) is one of
